miR-126 in human cancers : clinical roles and current perspectives

Ebrahimi, Faeza, Gopalan, Vinod, Smith, Robert A., & Lam, Alfred King-Yin (2014) miR-126 in human cancers : clinical roles and current perspectives. Experimental and Molecular Pathology, 96(1), pp. 98-107.

[img] Published Version (PDF 539kB)
Administrators only | Request a copy from author

View at publisher


miR-126 has been implicated in the processes of inflammation and angiogenesis. Through these processes, miR-126 is implicated in cancer biology, but its role there has not been well reviewed. The aim of this review is to examine the molecular mechanisms and clinicopathological significance of miR-126 in human cancers. miR-126 was shown to have roles in cancers of the gastrointestinal tract, genital tracts, breast, thyroid, lung and some other cancers. Its expression was suppressed in most of the cancers studied. The molecular mechanisms that are known to cause aberrant expression of miR-126 include alterations in gene sequence, epigenetic modification and alteration of dicer abundance. miR-126 can inhibit progression of some cancers via negative control of proliferation, migration, invasion, and cell survival. In some instances, however, miR-126 supports cancer progression via promotion of blood vessel formation. Downregulation of miR-126 induces cancer cell proliferation, migration, and invasion via targeting specific oncogenes. Also, reduced levels of miR-126 are a significant predictor of poor survival of patients in many cancers. In addition, miR-126 can alter a multitude of cellular mechanisms in cancer pathogenesis via suppressing gene translation of numerous validated targets such as PI3K, KRAS, EGFL7, CRK, ADAM9, HOXA9, IRS-1, SOX-2, SLC7A5 and VEGF. To conclude, miR-126 is commonly down-regulated in cancer, most likely due to its ability to inhibit cancer cell growth, adhesion, migration, and invasion through suppressing a range of important gene targets. Understanding these mechanisms by which miR-126 is involved with cancer pathogenesis will be useful in the development of therapeutic targets for the management of patients with cancer.

Impact and interest:

38 citations in Scopus
Search Google Scholar™
45 citations in Web of Science®

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 74503
Item Type: Journal Article
Refereed: Yes
Additional Information: Ebrahimi, Faeza
Gopalan, Vinod
Smith, Robert Anthony
Lam, Alfred King-Yin
United States
Exp Mol Pathol. 2014 Feb;96(1):98-107. doi: 10.1016/j.yexmp.2013.12.004. Epub 2013 Dec 22.
Additional URLs:
Keywords: Humans, MicroRNAs/ genetics, Neoplasms/ diagnosis/genetics/ therapy, Tumor Markers, Biological/ genetics, miR-126, Carcinoma, Cancer
DOI: 10.1016/j.yexmp.2013.12.004
ISSN: 1096-0945
Subjects: Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200) > Cancer Genetics (111203)
Divisions: Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
Copyright Owner: Copyright 2014 Elsevier
Deposited On: 29 Jul 2014 23:11
Last Modified: 02 Aug 2014 16:58

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page